For example, the use of PPAR-δ and PPAR-γ agonists L165,041 and F-L-Leu, respectively, has shown positive changes in brain slices from i.c.v STZ injected rats: decreased inflammation, improved mitochondrial function and reduced Aβ neurotoxicity, although lipid peroxidation and cholinergic function were not rescued (Reich et al., 2018), suggesting that PPAR ligand therapies should be thought as complementary treatments in AD-like pathology. This evidence concerns the gene PPARA and Alzheimer disease.